Introduction
In previous studies we optimized a series of sulfamoylated estratrienes based around 2-methoxyestradiol derivatives as anti-cancer agents. [1] [2] [3] [4] [5] [6] These agents were developed as part of a programme addressing design of inhibitors of the emerging drug target steroid sulfatase (STS). 7 In particular, an aryl sulfamate pharmacophore motif imbued potent irreversible inhibition against STS and drugs bearing this motif entered clinical trials, primarily in oncology. The sulfamoylated estratrienes also showed potent STS inhibitory activity. 6 These also exhibit potent anti-proliferative activity against a range of human cancer 3 cell lines and also inhibit angiogenesis. This dual mechanism of action can be ascribed to inhibition of normal microtubule dynamics. In addition to good oral bioavailability and excellent in vivo activity, 7 they proved capable of inhibiting the growth of cell lines resistant to existing microtubule disruptors such as the taxanes. To develop further series of compounds sharing this mechanism of action, we were drawn to investigate whether, by translating the three key pharmacophore elements from a sulfamate steroidal compound series 1 (eg 1a (STX140), Figure 1 ) into non-steroidal motifs, we could generate new microtubule disruptors with enhanced activity and particularly more useful physicochemical
properties. In initial studies, [8] [9] we used a tetrahydroisoquinoline (THIQ) decorated at C-6 and C-7 to mimic the steroidal AB-rings, tethered through N-2 to a D-ring mimic, initially a benzyl group. This projects a hydrogen bond acceptor into the appropriate region of space to address the pharmacophore for anti-proliferative activity in that region. This preliminary work delivered a series of microtubule disruptors with anti-proliferative activity in the micromolar range, demonstrating also enhanced activity for the sulfamoylated phenols, and this activity could be further optimized by introducing a substituent at C-3 to sterically inhibit the free rotation of the N-benzyl group. This manoeuver favored a conformational population in which the N-benzyl group is in proximity to the steroidal D-ring; in this manner compounds displaying nanomolar activity (equivalent to the steroidal derivatives upon which their design was based) were elaborated. 10 In tandem, related chimeric microtubule disruptors built from the THIQ core and the trimethoxy aryl motif common to many colchicine site binders on tubulin were constructed. [11] [12] In the present work, we aimed to utilize a similar strategy for the discovery of new microtubule disruptors, but extend our previous efforts by incorporating an achiral steric buttress to achieve conformational biasing. Having earlier successfully mimicked the steroidal AB-ring system with the 6,6-bicyclic THIQ core and achieved enhanced activity by substituting at C-3, with concomitant introduction of chirality, we were drawn to construct 3,4-dihydroquinazolin-2(1H) We reasoned that the carbonyl group at C-3 should clash with the N-2 substituent that would then prefer to adopt a conformation in which it projects into the area of space close to that of a mimicking steroidal D-ring. This would place a hydrogen bond acceptor group at a near optimal position for target site interaction. By introducing 2'-, 3'-and 4'-methoxybenzyl groups at N-2 we envisaged that prototypical hits could be obtained. Should such hits be identified, a small screening set could be constructed to afford a preliminary SAR.
Results and Discussion

Chemistry
The candidate DHQs were duly synthesized in a five step linear synthesis for each sulfamate derivative of type 7 starting from 4-benzyloxy-5-methoxy-2-nitrobenzaldehyde 2. 13 Reductive amination of 2 with the corresponding benzylamine in the presence of sodium triacetoxyborohydride in chloroform gave compounds 3a-k. Subsequent reduction of the nitro group using Raney nickel and hydrazine hydrate in methanol furnished the corresponding anilines 4a-k in very good yields. Reaction of 4a-k with urea at 220 °C delivered the protected quinazolinones 5a-k. These were transformed into the unprotected phenols 6a-k either by treatment with hydrogen and palladium on carbon (Pd/C) or with 5 methanesulfonic acid in dichloromethane (for 5f) and finally into the target sulfamates 7a-k using sulfamoyl chloride in N,N-dimethylacetamide (DMA) 14 (Scheme 1). 
Biology
The in vitro activities of the DHQs and their sulfamates against the proliferation of DU-145 prostate and MDA MB-231 breast cancer cell lines were determined and are presented in Table 1 and are benchmarked against literature data for combretastatin A-4 (CA-4). Data obtained for both cell lines are in good agreement, and therefore, for clarity of SAR discussion, only the figures obtained with the DU-145 cells are discussed further. Compounds 6a and 7a, both of which lack a hydrogen bond acceptor and thus one component of the steroidal pharmacophore for microtubule disruption, proved inactive, as expected. The results obtained for the simple methoxybenzyl DHQs were more encouraging. While the 4'-methoxy and 3'-methoxy derivatives showed at best modest activity (7c GI 50 33 µM), the 2'-methoxy derivative proved extremely interesting, with the 6-hydroxy compound and its 6-O-sulfamate, 6 respectively, exhibiting micromolar and nanomolar GI 50 's. This finding, that sulfamate 7b was more active than 6b, is in agreement with the steroidal series, wherein sulfamoylation of the phenol typically results in a 10-fold or greater increase in activity. In this case, and for later members of the DHQ series, this rule of thumb holds well (GI 50 's of 0.3 µM and 2.2 µM for 7b and 6b respectively). These preliminary results indicated that 2'-substitution was worthy of further investigation, and a second set of phenols 6e-k and their sulfamates 7e-k was elaborated. Groups of similar steric size but differing electronic properties were introduced at the 2'-position, the lipophilic methyl group afforded little gain of activity, while the small fluoro substituent improved activity only modestly (7g GI 50 4.8 µM). In strong contrast, the 2'-chloro derivative 7f, which offers unhindered H-bond acceptor potential, showed excellent activity (GI 50 0.5 µM), thus providing support for our working hypothesis that decorating a non-steroidal system with appropriate functionality and arrangement to satisfy the established steroidal pharmacophore should yield novel microtubule disruptors. The 3'-chloro compound 7h proved significantly more active (ca 10-fold) than the corresponding 3'-methoxy compound 7c, suggesting that 3'-substitution was not necessarily deleterious to activity and also confirming that 2'-substitution is highly favored. Two dimethoxy analogues were also evaluated, with 2',3'-and 2',5'-substitution being selected on the grounds that the inductive effect of a second methoxy group might increase the electron density on the 2'-methoxy and thus enhance H-bonding. The 2',3'-dimethoxy compound 7i proved less active than 7b, suggesting that the additional methoxy at the 3'-position hinders binding, presumably on steric grounds.
The 2',5'-dimethoxy compound 7j (GI 50 50 nM), in contrast, was 6-fold more active than 7b, indicating that enhanced hydrogen bonding may have resulted from the increased electron density on the 2'-methoxy derivative, although additional electrostatic or lipophilic interactions at the 5'-position could equally underlie this improvement in activity. The final compound to be evaluated was the 3',4',5'-trimethoxy compound 7k, which also displayed excellent activity (GI 50 0.1 µM). We selected this trisubstituted motif for further evaluation, since the trimethoxyphenyl moiety is common to many 8 strong activity for compounds bearing this motif. 11 In that case, however, the SAR varied from that of our steroidomimetic THIQs, and we considered that such derivatives should be considered chimeras of both our steroidal microtubule disruptors and trimethoxyaryl colchicine site binders. Whether 7k can be considered a chimeric microtubule disruptor is an open question, and further studies will be required for a definitive answer. In any case, it is a welcome additional lead from our comparatively small discovery compound set.
With these excellent in vitro data in hand, we then established the microtubule disruptor activity of compounds 7b, 7f and 7i-k alongside the established potent microtubule disruptor CA-4 ( Table 2 ). The 2′-methoxy and 2′,5′-dimethoxy derivatives 7b and 7j both inhibit tubulin assembly very effectively with an IC 50 of 2.5 µM and are only 2-to 3-fold less active than CA-4 itself. The concentration required in tubulin-based assays greatly exceeds the anti-proliferative dose; most likely it suffices to disrupt microtubule dynamics to arrest the cell cycle rather than causing a catastrophic depolymerization event.
Also, the nominal compound concentration in anti-proliferative assays is that of agent added to the culture medium, rather than the actual concentration within cells. We also determined that 7b, 7f and 7j
inhibit colchicine binding to tubulin, with 7j being the best, showing 61% inhibition at 5 µM. It thus appears reasonable to suggest that the interaction of the novel quinazolinones can at least partially be ascribed to their ability to disrupt the normal dynamic polymerization of tubulin by interaction at the colchicine binding site. We thus chose to explore this idea further using structural biology techniques. In order to determine the binding mode of these DHQ derivatives (Figure 2a) within the αβ-tubulin heterodimer, we soaked the most potent compound 7j into a T 2 R-TTL crystal 16 and solved the T 2 R-TTL-7j complex structure by X-ray crystallography to 2.1 Å resolution (Figures 2b, 3a ; Table S1 see also Supplementary Information). 7j binds to the colchicine site of tubulin 17 at the intradimer interface and interacts with residues from the strands βS8 and βS9 and helix βH8 of β-tubulin and from the loop αT5 of α-tubulin (Figure 3a) . A molecule of GTP was also observed bound to the α-subunit. As anticipated from the design considerations 7j presents in an extended "steroid-like" conformation. The compound is well accommodated within the colchicine site, which undergoes significant conformational changes located at both the βT7 and αT5 loops of tubulin upon ligand binding (Figure 4) . To the best of our knowledge this is the first co-crystal structure of an anti-tubulin agent possessing a sulfamate group.
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The compound is anchored into a hydrophobic pocket which is part of the β-tubulin subunit and formed by residues βLeu242, βLeu255, βCys241, βMet259, βAla316 and βAla354 (Figure 3a) . Its interaction is further stabilized by hydrogen bonds mediating contacts mainly between the sulfamate group and the side chains of βLys352, βAsn349 and αSer178, the amine group of the main chain of αVal181 and the carbonyl group of the main chain of βAsn349. A supplementary water-mediated interaction (HOH) is formed between the amine group of the ligand's B ring and the carbonyl groups of the side chain and main chain of αAsn101 and αThr179, respectively (Figures 3a and 3b) . Given this apparently available space, further medicinal chemistry development of these DHQs could include attempting to mimic at least one of these interactions by substitution on the NH of the B ring with suitably-sized substituents (eg N-methylenehydroxy, N-methyleneamino and N-sulfonamide groups). 12 respective A rings and associated methoxy groups of 7j and colchicine superimpose very well. We found that 7j is more deeply inserted into the binding pocket than colchicine and that both compounds share a unique common polar interaction with the amine group of the main chain of αVal181. and secondary structure elements are labeled.
Free tubulin undergoes a characteristic "curved-to-straight" conformational change upon polymerization into microtubules. [17] [18] This conformational change involves an overall compaction of the colchicine binding site involving mainly the βT7 loop and βS8 strand of the β-tubulin chain. 17 To investigate the binding of 7j in the context of a microtubule, we superimposed both β-tubulin chains from a "straight" tubulin structure (PDB ID 3JAR) and our tubulin-7j structure (RMSD chainD "straight" onto chainD 7j 0.7 Å over 1609 atoms; Figure 5 ). We observe that upon binding to free tubulin, compound 7j prevents the compaction of the colchicine site, by sterically hindering the accommodation of the βT7 loop and βS8 strand that occlude the colchicine binding site. Presumably, the extra interactions of the 7j sulfamate group vs colchicine itself further strengthens this effect. Thus, 7j is expected not to be able to bind to the colchicine sites in preformed microtubules. In summary, these results establish compound 7j as a colchicine site tubulin binding ligand. They further suggest that, similar to other colchicine site ligands, 17, 19 the mechanism of microtubule destabilization by 7j is to prevent the curved-to-straight tubulin conformational transition.
All sulfamoylated compounds of type 7 and one phenol of type 6 were also tested for steroid sulfatase (STS) inhibition (structures see also S4 in SI). STS Inhibition is a new strategy for endocrine therapy, 7 as for the well-established aromatase inhibition. As a comparison, some previously synthesized tetrahydroisoquinoline derivatives 8-14 9, [11] [12] and the well-known potent inhibitor irosustat 15 7, 20 (all structures see S5 in SI) were also evaluated alongside the quinazolinone derivatives, with the expectation that, like most aryl sulfamate esters, 6-7 they would show good STS inhibitory activity.
However, at 10 µM only compounds 7b, 7f and 7h showed weak activity (see S6a in SI). At 100 µM, however, the same three compounds inhibited STS by about 70-80% (Figure 6a) , with other compounds also starting to show weak activity. It seems that substitution in the 2'-position of the C-ring 14 of the DHQs is favorable to obtain weak STS inhibition, with 7f (2'-Cl) and 7b (2'-MeO) being about equally active. Compounds with other substituents in the 2-position, like 7e (2'-Me) and 7g (2'-F), are weakly active, with an inhibition of about 20-25% at 100 µM. At the 3'-position of the C-ring, only some small H-bond acceptors like Cl are tolerated (7h), in contrast to MeO (7c), which is not. It seems though that overall there is still some H-bond acceptor property required in the C-ring to obtain at least some STS inhibition, as the all H-substituted compound 7a proved inactive. All di-or tri-substituted compounds of type 7 and 6j were also inactive even at the higher 100 µM concentration (Figure 6a) .
Remarkably, this also included compounds 7j and 7k, which showed excellent in vitro anti-proliferative activity against both cancer cell lines. Of the earlier non-steroidal tetrahydroisoquinoline (THIQ) derivatives 8-14 evaluated, only compound 9 showed some weak STS inhibition (about 45% at 100 µM). Irosustat 15 was used as a positive control and was, as expected, highly potent, with near total STS inhibition at both concentrations. 
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The weak activity towards STS of both DHQ and THIQ classes of compound was unexpected, since generally aryl sulfamate esters are highly active on STS. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 exploration and development as CAIX inhibitors, as sulfamate esters are known to imbue CAIX inhibitory and modulatory activities, 21 and this is an emerging area of clinical interest. 22 On the basis of its promising in vitro activity, 7b was selected as an early lead for a preliminary evaluation in an RPMI 8226 in vivo xenograft model of multiple myeloma (see S7a and S7b in SI). The compound was dosed alongside vehicle at 20 mg/kg and 40 mg/kg orally for 28 days (the standard doses and regime used for the earlier steroidal and non-steroidal systems explored). 9 A statistically significant reduction in tumor growth of 27% and 31%, respectively, was observed at the two doses at day 53 (18 days after cessation of treatment). Future studies, preferably with 7j or a more active compound should ideally be preceded by pharmacokinetic evaluation. Importantly, this non-steroidal system was clearly well-tolerated in vivo, with the sulfamate moiety likely contributing to oral bioavailability. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 peripheral neuropathy and neutropenia, which are often dose-limiting. Additionally, we have shown the efficacy of non-steroidal derivatives of STX140 12 in xenograft models in vivo 26 and more widely 27 and that such drug candidates interact with tubulin and can be active in models of clinical taxane resistance. 26 While it has yet to be shown more widely that such non-steroidal sulfamate esters confer all of the above advantages shown by STX140, it is notable that the present work reports the first example of such an agent in atomic detail bound to tubulin dimer, as determined by structural biology techniques.
It is highly encouraging that the sulfamate group is not only well-accommodated, but also makes positive interactions in the colchicine site. Colchicine itself has often been linked to adverse toxicity, and there is currently no colchicine site microtubule disruptor approved in oncology, although agents are, and have been, in clinical trials. Compound 7j and similar quinazolinone sulfamates may thus be promising leads as novel antitubulin agents with desirable physicochemical and biological properties for oncology. The atomic level detail of the tubulin-7j structure reported here, moreover, shows opportunities for application of medicinal chemistry to improve interactions further with the colchicine site. Taken together, these results justify the wider exploration of these quinazolinones and of sulfamatebased agents in oncology.
Conclusions
Quinazolinone-based microtubule disruptors with excellent in vitro activities combined with desirable drug-like profiles have been designed. The best compound 7j shows anti-proliferative activity in the 50 nM range, inhibits tubulin assembly and also interferes effectively with the colchicine site. 7j was successfully co-crystallized with the αβ-tubulin heterodimer and found to bind more deeply in the colchicine binding site than colchicine itself, with the sulfamate group involved in the binding process through specific interactions with β-tubulin. This is the first example of a sulfamate ester bound to tubulin explored crystallographically. The results suggest that the mechanism of microtubule destabilization by 7j is to prevent the curved-to-straight tubulin conformational transition that is Tubulin Assays. Bovine brain tubulin, prepared as described previously, 28 was used in the studies presented here. Assembly IC 50 's were determined as described in detail elsewhere. 29 Briefly, 1.0 mg/mL 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 19 (10 µM) tubulin was preincubated without GTP with varying compound concentrations for 15 min at 30
°C. Reaction mixtures were placed on ice, and GTP (final concentration, 0.4 mM) was added. The reaction mixtures were transferred to cuvettes, held at 0 °C in a recording spectrophotometer. Baselines were established at 0 °C, and increase in turbidity was followed for 20 min following a rapid (< 30 s) jump to 30 °C. Compound concentrations required to reduce the turbidity increase by 50% were determined. The method for measuring inhibition of the binding of [ 3 H]colchicine to tubulin was described in detail previously. 30 Reaction mixtures contained 0.1 mg/mL (1.0 µM) tubulin, 5.0 µM 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   20 follows: chain A, α1-tubulin; chain B, β1-tubulin; chain C, α2-tubulin; chain D, β2-tubulin; Chains A and B were used throughout for the structural analyses and figure preparation.
In Vitro Sulfatase Assay: STS activity was measured as previously described. 33 Briefly, JEG-3 cells were lysed with RIPA buffer (Sigma-Aldrich, U.K.) and protein content determined using a BCA assay 
2-N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(2-methoxyphenyl)-methanamine 3b
Method as for 3a using compound 2 (5.8 g, 20 mmol), 2-methoxybenzyl amine (4. 
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(3-methoxyphenyl)-methanamine 3c
Method as for 3a using compound 2 (5. 
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-o-tolylmethanamine 3e
Method as 3a using compound 2 (5.8 g, 20 mmol), 2-methylbenzyl amine (3.6 g, 30 mmol) and sodium 
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(2-chlorophenyl)-methanamine 3f
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(2-fluorophenyl)-methanamine 3g
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(3-chlorophenyl)-methanamine 3h
Method as 3a using compound 2 (5.7 g, 20 mmol), 3- 
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(2,3-dimethoxyphenyl)-methanamine 3i
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(2,5-dimethoxyphenyl)-methanamine 3j
N-(4-Benzyloxy-5-methoxy-2-nitrobenzyl)-1-(3,4,5-trimethoxyphenyl)-methanamine 3k
Method as for 3a using compound 2 (5.7 g, 20 mmol), 3,4,5-trimethoxybenzyl amine (5. 
5-Benzyloxy-4-methoxy-2-((2-methoxybenzylamino)methyl)-aniline 4b
Method as for 4a using compound 3b (5.3g, 13 mmol), Raney Nickel (60%, 1.5 g) and hydrazine hydrate (10 x 0.2 mL in 10 min intervals) in MeOH (200 mL) at reflux for a total of 2 h. Flash column chromatography (PE→EtOAc) afforded compound 4b as a dark oil that slowly solidified (4. 
5-Benzyloxy-4-methoxy-2-((3-methoxybenzylamino)methyl)-aniline 4c
Method as for 4a using compound 3c (3.5 g, 8.6 mmol), Raney Nickel (60%, 1 g) and hydrazine hydrate (10 x 0.2 mL in 10 min intervals) in MeOH (200 mL) at reflux for a total of 2 h. Flash column chromatography (PE→EtOAc) afforded compound 4c as a dark oil that slowly solidified (2.8 g, 88%); 
5-Benzyloxy-4-methoxy-2-((4-methoxybenzylamino)methyl)-aniline 4d
Method as for 4a using compound 3d (6.7 g, 10.4 mmol), Raney Nickel (60%, 2 g) and hydrazine
hydrate ( 
5-Benzyloxy-4-methoxy-2-((2-methylbenzylamino)methyl)aniline 4e
Method as for 4a using compound 3e (5.1 g, 13 mmol), Raney Nickel (60%, 2 g) and hydrazine hydrate (10 x 0.25 mL in 10 min intervals) in MeOH (100 mL) at reflux for a total of 2 h. 
5-Benzyloxy-2-((2-fluorobenzylamino)methyl)-4-methoxyaniline 4g
Method as for 4a using compound 3g (4.8 g, 12.1 mmol), Raney Nickel (60%, 2 g) and hydrazine
hydrate (10 x 
5-Benzyloxy-2-((3-chlorobenzylamino)methyl)-4-methoxyaniline 4h
Method as for 4a using compound 3h (5 g, 12.1 mmol), Raney Nickel (60%, 2 g) and hydrazine hydrate (10 x 0.25 mL in 10 min intervals) in MeOH (150 mL) at reflux for a total of 2 h. 
5-Benzyloxy-2-((2,5-dimethoxybenzylamino)methyl)-4-methoxyaniline 4j
Method as for 4a using compound 3j (3 g, 6.8 mmol), Raney Nickel (60%, 1 g) and hydrazine hydrate (10 x 0.2 mL in 10 min intervals) in MeOH (100 mL) at reflux for a total of 2 h. 
5-Benzyloxy-4-methoxy-2-((3,4,5-trimethoxybenzylamino)-methyl)aniline 4k
Method as for 4a using compound 3k (6 g, 12.8 mmol), Raney Nickel (60%, 2 g) and hydrazine hydrate 
7-Benzyloxy-6-methoxy-3-(2-methoxybenzyl)-3,4-dihydroquinazolin-2(1H)-one 5b
Method as for 5a using compound 4b (0.7 g, 1.85 mmol) and urea (0.7 g, 11.7 mmol). 7-Benzyloxy-6-methoxy-3-(3-methoxybenzyl)-3,4-dihydroquinazolin-2(1H)-one 5c
Method as for 5a using compound 4c (0.75 g, 1.97 mmol) and urea (0.8 g, 13.3 mmol) at 220 °C for 1.5
h. Flash column chromatography (PE/EtOAc 5:1→1:4) gave a solid that was stirred in Et 2 O, filtered and dried to afford compound 5c as a yellow powder (340 mg, 43%); mp 136-138 °C. 1 7-Benzyloxy-6-methoxy-3-(4-methoxybenzyl)-3,4-dihydroquinazolin-2(1H)-one 5d
H NMR (270 MHz
Method as for 5a using compound 4d (0.7 g, 1.85 mmol) and urea (0.7 g, 11.7 mmol) at 220 °C for 1. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 32 Method as for 5a using compound 4f (3.8 g, 9.9 mmol) and urea (3.6 g, 60 mmol) at 220 °C for 1 h. The resulting solid was cooled to rt and stirred in CHCl 3 (100 mL). 7-Benzyloxy-3-(2-fluorobenzyl)-6-methoxy-3,4-dihydroquinazolin-2(1H)-one 5g
Method as for 5a using compound 4g (3.6 g, 9.8 mmol) and urea (3.6 g, 60 mmol) at 220 °C for 1 h.
The resulting solid was cooled to rt and stirred in CHCl 3 (100 mL). 
7-Benzyloxy-3-(3-chlorobenzyl)-6-methoxy-3,4-dihydroquinazolin-2(1H)-one 5h
Method as for 5a using compound 4h (3.4 g, 8.9 mmol) and urea (3.0 g, 50 mmol) at 220 °C for 0.5 h.
The resulting solid was cooled to rt and stirred in CHCl 3 (100 mL). Method as for 5a using compound 4i (3.0 g, 7.3 mmol) and urea (4.5 g, 74.9 mmol) at 220 °C for 1 h.
7-Benzyloxy-3-(2,5-dimethoxybenzyl)-6-methoxy-3,4-dihydroquinazolin-2(1H)-one 5j
Method as for 5a using compound 4j (2. 7-Hydroxy-6-methoxy-3-(3-methoxybenzyl)-3,4-dihydroquinazolin-2(1H)-one 6c
35
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Method as for 7a using compound 6i (117 mg, 0.35 mmol) and sulfamoyl chloride (1.4 mmol) in DMA ( 
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